Table 2 Cost-effectiveness and threshold prices under varying programmatic assumptions (2012 US$)*
|  |  | Cost per DALY averted at $0.25 per dose | Microbicide threshold prices where $/infection averted (IA) = VMMC (~$1000/IA) | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | 2 doses per sex-act | 1 dose per sex-act | 2 gels per sex-act | Â | ||
Baseline programme: 3 annual HIV tests, 3 gel collection visits | Â | $297 | Â | Â | Â | $0.12 | Â |
Variations to distribution services | Â | Â | Â | Â | Â | Â | Â |
HIV tests per year | 2 | $190 | -36% | -$29 | -137% | $0.19 | 49% |
| Â | 4 | $405 | 36% | $186 | 137% | $0.06 | -49% |
| Â | 6 | $619 | 108% | $401 | 411% | Cannot be achieved | Â |
Adherence counselling and gel collection visits | 2 | $272 | -9% | $53 | -32% | $0.14 | 12% |
| Â | 6 | $374 | 26% | $155 | 97% | $0.08 | -35% |
Integrated adherence counselling and gel collection into HIV testing (3) | Â | $221 | -26% | $2 | -97% | $0.17 | 35% |